Study of a new drug for hard-to-treat AML or high-risk MDS
Part of Blood & lymphatic, Cancer clinical trials.
This early study tests a new medicine (ABD-3001) to see if it’s safe and tolerable, how the body handles it, and whether it shows early signs of helping people with relapsed or hard-to-treat AML or high-risk MDS. It may be an option if standard treatments have already failed and you can’t receive a stem cell transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have relapsed or refractory AML that did not respond to at least one treatment plan, or you cannot get the usual “salvage” (re-treatment) plans.
- OR you have relapsed or refractory MDS that is high-risk or very high-risk (based on a scoring system), and you are not eligible for salvage treatment.
- You are not eligible for an allogeneic stem cell transplant (alloSCT).
- You are able to take part in study visits and start treatment, with no anti-cancer therapy in the 14 days before Day 1.
- You cannot have certain genetic types of AML (like inv(16), t(8;21), or PML/RARA) if you could instead get targeted treatment.
- You must not have active serious infections needing IV antibiotics, recent chemo/radiation, a recent stem cell transplant, or uncontrolled medical problems that would affect safety.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an oral investigational drug (GLB-001) for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or hasn't responded to other treatments. The goal is to see if it's safe and effective for those who have run out of standard options.
This early-phase trial tests whether a combination of targeted medicines can improve outcomes in people with higher-risk MDS or certain types of AML or CMML. It’s designed to find the safest dose and learn if the treatment can help the cancer respond.
This trial tests an experimental drug, BH-30236, for people with acute myeloid leukemia (AML) or a high-risk form of myelodysplastic syndrome (MDS) whose cancer has come back or stopped responding to treatment. It aims to see if the drug can help control the disease.
This Phase 1 trial tests BL-M11D1, a drug designed to target CD33 found on certain AML cells, in adults whose AML has come back or is hard to treat. If you qualify, you may be offered early access to a potential new option while researchers closely monitor safety and side effects.
This trial tests a new drug for people with acute myeloid leukemia (AML) that has come back or hasn't responded to standard therapies, and whose leukemia has certain genetic markers. The drug may target these specific changes to help stop the cancer.
This trial tests a new drug called GEN3018 for people with acute myeloid leukemia (AML) or higher-risk myelodysplastic syndrome (MDS) that has come back or not responded to standard treatments. It aims to see if the drug is safe and effective.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.